 |
|
|
| |
Sofosbuvir-Based Regimens for Patients with Hepatitis C Virus Genotype 3 Infection:
Summary Results from the VALENCE, BOSON, LONESTAR-2, and ELECTRON-2 Studies
|
| |
| |
Reported By Jules Levin
DDW 2015 - Digestive Disease Week 2015, May 16-19, 2015, Washington D.C.
EASL: Sofosbuvir Plus Peg-IFN/RBV for 12 Weeks vs Sofosbuvir/RBV for 16 or 24 Weeks in Genotype 3 HCV-Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study - (04/27/15)
E Lawitz1, S Zeuzem2, CA Stedman3, F Poordad1, HM Mir4, S Seyedkazemi4, RH Hyland4, PS Pang4, DM Brainard4, JG McHutchison4, EJ Gane5
1Texas Liver Institute, San Antonio, TX, USA; 2Johann Wolfgang Goethe University, Frankfurt, Germany; 3Christchurch Hospital and University of Otago, Christchurch, New Zealand; 4Gilead Sciences, Foster City, CA, USA; 5New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
|
| |
|
|
|
|
|
